SCHEMBL31122401

SCHEMBL31122401

COC(=O)c1ccc2cc[nH]c2c1S(C)(=O)=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR3C1 P04150 1/20 0.40
▸ PGR P06401 1/20 0.40
▸ NR3C2 P08235 1/20 0.40
▸ AR P10275 1/20 0.40
▸ PIM3 Q86V86 2/20 0.39
▸ PIM1 P11309 1/20 0.39
▸ KDM4E B2RXH2 2/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ BCHE P06276 2/20 0.38
▸ KEAP1 Q14145 1/20 0.37
▸ CHEK1 O14757 2/20 0.37
▸ PDPK1 O15530 1/20 0.36
▸ GLA P06280 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ IKBKB O14920 1/20 0.36
▸ CHUK O15111 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ MAOB P27338 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25363572 1.00 NR3C1 (0.40) NR3C1PGRNR3C2ARPIM3
SCHEMBL30456277 0.83 KEAP1 (0.51) NR3C1PGRNR3C2ARKDM4E
SCHEMBL1162240 0.78 KDM4E (0.42) PIM3PIM1KDM4EBCHEKEAP1
SCHEMBL12869670 0.78 NR4A2 (0.42) PIM3PIM1KDM4EBCHEKEAP1
SCHEMBL14559837 0.77 TNF (0.46) PIM3PIM1KDM4ESMN1; SMN2BCHE
SCHEMBL23551487 0.77 PIM3 (0.41) PIM3PIM1KDM4ESMN1; SMN2BCHE
SCHEMBL24308142 0.77 CHEK1 (0.45) PIM3PIM1KDM4EBCHEKEAP1
SCHEMBL987448 0.75 IKBKB (0.43) PIM3PIM1KDM4ESMN1; SMN2HSD17B10
SCHEMBL25362273 0.73 ALDH1A1 (0.43) PIM3PIM1KDM4EHSD17B10BCHE
SCHEMBL31122414 0.73 PIM3 (0.41) PIM3PIM1KDM4EHSD17B10BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250145632-A1 Pyrimidine Heterocyclic Compound, Preparation Method Thereof and use Thereof in Medicine INSILICO MEDICINE IP LIMITED (HK) 2025-05-08 — — US disclosed
EP-4455132-A1 PYRIMIDINE HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE Insilico Medicine IP Limited (HK) 2024-10-30 — — EP disclosed
CN-118647607-A Pyrimidine heterocyclic compounds, process for preparing the same and pharmaceutical use thereof 英矽智能科技(上海)有限公司 2024-09-13 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250145632-A1 Pyrimidine Heterocyclic Compound, Preparation Method Thereof and use Thereof in Medicine DPYD, TYMP, NUDT1 NR3C1 2017/4885PGR 699/4885NR3C2 1273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback